Apellis Pharmaceuticals Is Trading Near Its 52-Week High. Most Analysts Think It Shouldn't Be.

The Syfovre story

Apellis's commercial trajectory is built almost entirely on two products: Syfovre (pegcetacoplan injection), the first FDA-approved treatment for geographic atrophy (GA) secondary to age-related macular degeneration, and Empaveli (pegcetacoplan), approved for paroxysmal nocturnal hemoglobinuria (PNH) and, as of July 2025, for C3 glomerulopathy and primary immune complex-mediated glomerulonephritis. Syfovre is the revenue driver. The company reported total revenues of approximately $781 million in fiscal 2024, representing 97 percent year-over-year growth, with Syfovre capturing over 35 percent of the GA market by late 2024.

The Q3 2025 earnings report was the inflection point for the stock. Apellis reported earnings per share of $1.67, crushing the consensus estimate of $1.03, on revenue of $460 million against expectations of $200 million. That quarter included a gross margin of 94.7 percent and a net margin of 47 percent. It was the kind of blowout that forces analysts to reconsider their models.

But the quarters surrounding it were less impressive. Q1 2025 showed a net margin of negative 55.3 percent. Q2 came in at negative 23.6 percent. And Q4 2025, the most recent quarter reported (on February 24, 2026), showed revenue of $200 million (roughly in line with estimates) but a net margin of negative 29.5 percent and EPS of negative $0.47, missing the consensus estimate of negative $0.39. Revenue in Q4 declined 5.9 percent year over year.

The quarterly volatility raises a question the stock price has so far ignored: was Q3 2025 the beginning of a new trajectory, or an outlier?

The analyst gap

Wall Street's consensus on Apellis is "Moderate Buy," with 18 analysts rating the stock a Buy or Strong Buy, six at Hold, and one at Sell. But the price targets tell a different story. The median target sits at $30.50. The high is $52. The low, from Goldman Sachs, is $19.

At $40.35, Apellis trades 32 percent above the median target and more than double Goldman's bear case. Royal Bank of Canada cut its target to $21 in late February with a "sector perform" rating. Barclays initiated coverage in January at $24 with an "equal weight" rating. The analysts who are most bullish (William Blair reiterated "outperform" in December) have not published updated targets that account for the stock's recent surge.

In other words: the stock has moved faster than the analysts covering it. That is not inherently bearish, but it does mean the current price embeds expectations that most published models do not support.

Insider activity and institutional flows

CEO Cedric Francois sold 27,192 shares on January 22 at $21.77 per share, a transaction worth approximately $592,000. Chief Commercial Officer Mark Jeffrey Delong sold 3,371 shares the same day at the same price. In total, insiders sold 115,537 shares worth roughly $2.5 million in the most recent quarter. Company insiders still own 6.5 percent of the stock.

To be sure, insider sales at pre-commercial and early-commercial biotech companies are routine, often driven by tax planning, options expiration, or diversification rather than bearish conviction. Francois has led Apellis since its founding in 2009 and retains a substantial position. But the sales occurred at prices between $21 and $22, roughly half where the stock trades today.

On the institutional side, the picture is more constructive. SG Americas Securities increased its position by 35.9 percent in Q4, adding nearly 150,000 shares. Hedge funds and institutional investors collectively own 96.29 percent of the company's stock.

What explains the rally

The stock's 136 percent move from its 52-week low is not a mystery. Apellis navigated a genuine crisis in mid-2023, when reports of rare retinal vasculitis after Syfovre injections triggered label updates and a roughly 40 percent decline in the share price. The all-time high of $94.75 (set in June 2023) was followed by a prolonged selloff that took the stock below $17 by early 2025.

The recovery reflects three developments: Syfovre's safety profile stabilized in post-marketing data (the company published an incidence rate of approximately 0.01 percent per injection for severe retinal vasculitis); the Q3 2025 earnings blowout demonstrated commercial viability; and the July 2025 Empaveli label expansion into C3G and IC-MPGN opened what management has described as a potentially $1 billion addressable market.

But the stock remains 57 percent below its all-time high, and the path from $40 to $95 requires sustained profitability that the quarterly earnings data has not yet demonstrated. The next earnings report (scheduled for May 6, 2026) will be closely watched: analysts expect revenue of approximately $200 million and EPS of negative $0.38.

The bottom line

Apellis Pharmaceuticals is a company whose product (Syfovre) addressed a genuine unmet need, whose safety scare proved manageable, and whose stock has staged a remarkable recovery. The flat trading day on Monday is unremarkable in isolation. What is remarkable is the gap between where the stock sits and where the analysts who cover it think it should be. Either the market is pricing in a sustained growth trajectory that the sell-side has not yet modeled, or the stock has gotten ahead of itself. The May earnings report will go a long way toward resolving that question.